- APPG on Pharmacy
- 15 October 2026
- News article
ADHD UK CEO Henry Shelford gave evidence to the All-Party Parliamentary Group on Pharmacy for its follow-up report on medicines shortages, which reviews progress since the group’s 2025 inquiry. He was one of the speakers at the oral evidence session in July 2026, alongside representatives from the Department of Health and Social Care, industry, wholesalers and pharmacy bodies.
The report highlights the ongoing shortages of ADHD medication as a clear example of the pressures still facing the system. It notes that rising demand, combined with stretched specialist services and limited GP capacity, has left some ADHD patients facing long waits to review or change their treatment when their medicine becomes unavailable.
Overall, the APPG found that progress has been made, with stronger collaboration, more attention on medicines security and better information sharing. However, many of the underlying problems remain, and national activity has not yet made a consistent difference for patients or pharmacy teams. The report sets out five priorities:
- Giving pharmacists more flexibility to supply alternatives during shortages.
- Improving visibility of shortages at the point of prescribing and dispensing.
- Strengthening forecasting and data sharing, so that shortages are prevented rather than only managed.
- Recognising resilience in pricing, reimbursement and procurement.
- Treating medicines security as a strategic national priority.
The APPG concludes that success should be measured by fewer avoidable disruptions for patients, rather than by the number of initiatives announced.

